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Summary: A number of serum components, whose concentrations or gene expression have been shown to be
modulated by all-trans retinoic acid in vitro, were monitored in patients before and during treatment with Roaccuta-
ne™ (13-c/s retinoic acid, 40—60 mg/day) for severe acne. The 13-cis retinoic acid concentration in serum rose
from 5.25 ± 1.09 to 593 ± 65 nmol/1 (mean ± SD) 24 h after the latest dose. The concentration of all-trans retinoic
acid in serum under Roaccutane™ treatment was measured in model experiments and shown to be 10—20 nmol/1
i.e., 2—4 times the basal levels (4.65 ± 0.85 nmol/1) when the 13-cis retinoic acid concentration was 370—980
nmol/1. The concentrations of creatine kinase-MB, apolipoprotein B, total cholesterol and LDL cholesterol increased
significantly while the other measured serum components, including lipoprotein lipase activity, were unaffected by
Roaccutane™ treatment.
Introduction
Vitamin A or all-trans retinoic acid has been shown to
influence the expression of several genes in vitro (1—5).
For example, all-trans retinoic acid concentration as low
as 1 nmol/1 (2) i.e. at concentrations well within the
physiological concentration range (4—6 nmol/1) in se-
rum (6, 7), increase the expression of the growth hor-
mone gene by several orders of magnitude. In some
cases a retinoic acid receptor response element has been
demonstrated in the promoter region of the genes of in-
duced proteins (5).
The administration of therapeutic doses of Roaccuta-
ne™ (13-cis retinoic acid) to humans (e. g. for the treat-
ment of severe acne) increases not only the concentra-
tion of 13-cis retinoic acid, but also the concentration of
all+trans retinoic acid, partly as a non-enzymatic process
(10). 13-cis Retinoic acid does not bind to retinoic acid
receptors and is probably inactive (9), while all-trans
retinoic acid is the biologically active retinoid that binds
to the retinoid receptors. As the half-life of all-trans reti-
noic acid is about 1/20 of that of 13-cis retinoid acid
(11, 12), the relative concentration of all-trans retinoic
acid in the tissues may be even higher than in serum.
All-trans retinoic acid has been shown to modify the
expression of a number of genes in vitro (1—5). To de-
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termine whether these actions of vitamin A/all-trans re-
tinoic acid are also demonstrable in vivo, we have mea-
sured the concentration of a number of serum compo-
nents which are related to these genes.
Materials and Methods
Patients
The patients were 18 males aged 17-31 years and 2 females aged
28 and 47 years who were given Roaccutane™ 40 or 60 mg/daily
as treatment for acne. Ten of the patients also received erythromy-
cin to attenuate initial "flare up" symptoms. They were all sub-
jectively healthy and were not taking any other medication. Serum
13-cis retinoic acid concentration was measured to ensure compli-
ance. Blood was drawn in vacuum tubes without additions, before
and after 6 weeks of treatment, as fasting morning samples, imme-
diately before the intake of the daily dose of Roaccutane™ (i. e.
24 h after the last dose). Serum was recovered by centrifugation
and stored in the dark at —20 °C until analysed.
During the course of the study we found that it was difficult to
completely avoid exposure of the patient samples to light, which
is known to facilitate isomerisatiori of \3-cis to all-trans retinoic
acid (10). Therefore, the concentrations of all-frans retinoic acid in
serum during Roaccutane™ treatment was estimated in separate
experiments in which we measured the levels of 13-cw and all-
trans retinoic acids in a volunteer at various times (4-24 h) after
intake of 50 mg Roaccutane™. These blood samples were col-
lected in vacuum tubes without addition, immediately wrapped in
aluminium foil to protect them from light, allowed to clot at room
temperature and transferred to a refrigerated swing-out centrifuge.
The resulting serum was handled in the dark or under yellow light.
The results of these measurements were used as an estimate of the
true serum concentration of all-fw/tt retinoic acid in patients on
Roaccutane™ treatment.
Since all components could not be measured in all patients due to
the limited amount of serum, each component was first measured
in five randomly chosen patient samples. If there was a consistent
difference (P < 0.05 between the concentrations in samples ob-
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tained before and during treatment) the same component was mea-
sured in 4—5 more patient sera. Some minor differences may be
have been missed with this approach, but all consistent effects of
Roaccutane™ have probably been detected.
Methods
The all-fraw and 13-cw retinoic acid preparations used as calibra-
tors were gifts from Hoffman LaRoche, Basel. Acetonitrile and
methanol were HPLC grade. All other chemicals were pa grade
unless otherwise specified. Retinoic acids (all-trans and 13-cis)
were determined using the HPLC system described by Wyss &
Bücheli (\3).
Collagen type I telopeptide and procollagen type I propeptide were
determined using a test kit from Orion (Turku, Finland) and intact
parathyrin, calcitonin and osteocalcin with test kits from INCSTAR
(Stillwater, MN, USA). Sex hormone-binding globulin and testo-
sterone were determined by radioimmunoassay (with locally devel-
oped antibodies) using purified human sex hormone-binding globu-
lin and pure testosterone as calibrators. Follitropin and lutropin
were determined with Amerlite kits (Kodak Clinical Diagnostics,
Amersham, UK) and somatotropin with a kit from Pharmacia
(Uppsala, Sweden). Retinol-binding protein was determined using
rocket electrophoresis with antibodies from DAKO (Copenhagen,
Denmark) and a calibrator from Behringwerke AG (Marburg, Ger-
many). Transthyretin and ceruloplasmin were determined turbidi-
metrically using antibodies from DAKO (Copenhagen, Denmark)
and CRM 470-CAP-IFCC (Lot 91/0619) as calibrator. Apolipo-
protein A-I and apolipoprotein B were determined turbidimetrically
using antibodies and calibrators from Roche (Basel, Switzerland)
and lipoprotein(a) and ß2-microglobulin with antibodies and cali-
brators from DAKO (Copenhagen, Denmark). Alkaline phospha-
tase2), creatine kinase2) isoenzyme MB, triacylglycerol, cholesterol
and HDL cholesterol were determined using an Ektachem 700 XR-
C. LDL cholesterol was calculated according to Friedewald et al.
(14).
Lipoprotein lipase and hepatic lipase activities were determined in
postheparin plasma (15) before and after 6 weeks of Roaccutane™
treatment. The protocol was approved by the local ethics commit-
tee. Data are given as mean ± SD. The significance of differences
was evaluated using Wilcoxon's signed rank test.
Results
The serum concentrations of all-trans and 13-cis retinoic
acid in the patients before Roaccutane™ treatment was
4.65 ± 0.85 and 5.25 ± 1.09 nmol/1 (N = 20) respec-
tively. The reference intervals (derived from 80 blood
donors, 40 males and 40 females 20-60 years old) were
3.50-7.30 and 2.60-8.20 nmol/1 for all-trans and 13-
cis retinoic acid, respectively. The levels of all-trans and
13-czs· retinoic acid in serum increased as a result of
Roaccutane™ treatment. The concentration of 13-cis re-
tinoic acid in the patients (samples drawn 24 h after the
latest dose) was 180-1800 nmol/1 (mean 593 nmol/1).
The concentration of all-trans retinoic acid in serum
(measured in model experiments only, see Methods sec-
tion) was 2-3 percent of the concentration of 13-cis
retinoic acid in the concentration range of 370-890
nmol/1 13-cis retinoic acid. The concentrations of all-
2) Enzymes:
Creatine kinase (EC 2.7.3.2.)
Alkaline phosphatase (EC 3.1.3.1.)
trans and 13-cis retinoic acid in serum in these model
experiments were strongly correlated [all-trans retinoic
acid (nmol/1) = 0.021 X (13-cis retinoic acid (nmol/1)
+ 1.81; N = 8; r = 0.87; p < 0.001].
Inspection of the chromatograms shpwed that all sam-
ples contained substantial amounts of 4-oxo 13-cis and
4-oxo all-trans retinoic acid, which are the principal me-
tabolites of all-trans and 13-cis retinoic acids in man
(6,7).
Table 1 lists a number of proteins, whose gene expression
and synthesis in vitro has been shown to be influenced by
vitamin A/all-trans retinoic acid (1-5). The only compo-
nent which was affected in vivo during treatment with
Roaccutane™ was creatine kinase isoenzyme MB activ-
ity, the concentration of which increased significantly
(tab. 1). In many cases the enzyme activity exceeded the
upper reference limit of the laboratory, but it never
reached the values seen in myocardial infarction.
The components in table 2 were determined because
they are related to the components in table 1. Of these
variables, only the concentrations of cholesterol, LDL-
cholesterol and apolipoprotein B were increased as a re-
sult of Roaccutane™ treatment. Neither sex hormone-
binding globulin, the gonadotropins, the collagenases,
lipoprotein(a) nor the lipases were affected.
Discussion
The concentration of all-trans retinoic acid in serum
during Roaccutane™ treatment can be estimated at 10—
20 nmol/1, which is about 2-^4 times the normal level.
The half-life of all-trans retinoic acid in serum (11) is
considerably shorter than that of 13-cis retinoic acid (12)
(< 1 h, compared to < 17 h). Thus, the relative increase
in all-trans retinoic acid in the tissues may be even
greater than 2—4 fold.
The components in table 2 were chosen because they are
related to those in table 1. Thus, sex hormone-binding
globulin gene expression is stimulated by thyroid hor^
mones (17) in vivo, and thyroid hormone receptors and
the RXR series of retinoid receptors cooperate in regu-
lating the expression of thyroid hormone-responsive
genes (18). Somatotropin expression is regulated in vivo
by all-trans retinoic acid (2) and follitropin and lutropin
are, like somatotropin, pituitary gonadotropins. Since
collagen type I synthesis has been shown to be increased
by vitamin A (presumably all-trans retinoic acid) (19,
20) it seemed interesting to monitor both its synthesis
(measured as procollagen type I C-terminal propeptide
concentration in serum, tab. 1) and its degradation by
collagenases (measured as collagen type I telopeptide,
tab. 2).
Serum triacylglycerol and cholesterol concentrations
have been shown to be elevated, in a dose-dependent
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way, in individuals taking Roaccutane™ (21). The cause
is unknown. Therefore, we found it relevant (tab. 2) to
determine triacylglycerol, total cholesterol, low density
(LDL) and high density lipoprotein (HDL) cholesterol
concentrations, the concentrations of apolipoprotein A-I
(in tab. 1), apolipoprotein B, lipoprotein(a) and the activ-
ities of lipoprotein lipase and hepatic lipases. These li-
pases are major determinants of plasma lipoprotein con-
centrations and might be causally involved in the devel-
opment of hypercholesterolaemia and triglyceridaemia
during Roaccutane™ treatment. The triacylglycerol con-
centration in serum was not significantly increased in
these patients (tab. 2), possibly because Roaccutane™
dose was relatively low (21), or because we missed the
increase due to the design of the experiment.
The serum concentrations of total cholesterol, apolipo-
protein B and LDL cholesterol were significantly
increased during Roaccutane™ treatment (tab. 2). Apo-
lipoprotein A-I, lipoprotein(a) and HDL cholesterol (23)
concentrations were unaltered (tab. 2). Postheparin lipo-
protein lipase and hepatic lipase activities were not sig-
nificantly changed (tab. 1), which is in accord with other
studies (23, 24).
Experiments with primary cultures of primate liver cells
have shown that the transcription of the apolipoprotein
A-I gene is increased by retinoic acid while the expres-
sion of apolipoprotein B gene is unaffected (25). Other
experiments with all-trans retinoic acid show that the
expression of the apolipoprotein A-I gene is increased
in HepG2 cells and decreased in primary rat liver cell
cultures, and that the level of apolipoprotein A-I de-
creased in rat serum in vivo (26). We (tab. 2) and others
(27) found that the serum concentration of apolipoprot-
ein A-I is unchanged and that of apolipoprotein B is
increased during Roaccutane™ treatment. The increase
in serum LDL cholesterol (tab. 2) is in accord with pre-
vious studies (23) and is consistent with the increase in
apolipoprotein B concentration.
Tab. 1 Serum components (compiled in I.e. (1)) whose concen-
tration or gene expression has been shown to be affected by the
administration of vitamin A in vitro, before and after > 6 weeks
of Roaccutane™ (40—60 mg/day) to young adults (18 males and
2 females). Values are mean ± SD. Expected direction of change:
D = Decrease, I = Increase). (N = 5 except for creatine kinase-
MB isoenzyme, where N = 9). The reference intervals refer to men
and women 20—60 years old.
Component (Decrease/Increase)
Procollagen I propeptide (D)
Intact parathyroid hormone (I)
Osteocalcin (bone Gla protein) (I)
Calcitonin (D)
Retinol-binding protein (I)
Transferrin (I)
Transthyretin (I)
Ceruloplasmin (I)
Growth hormone (I)
Apolipoprotein A-I (D)
Alkaline phosphatase (D, I)
Creatine kinase-MB isoenzyme (I)
2-Microglobulin (I)
Unit
fog/I)(pmol/1)
frgfl)
fog/I)(mg/1)
(g/l)
(g/0
(g/l)
(mIU/1)
(g/l)
^kat/l)
^kat/l)
(mg/1)
Before treatment
200 ± 72
2.0 ± 0.9
7.4 ± 4.5
18.4 ± 7.2
40 ± 12
2.2 ± 0.4
0.29 ± 0.06
0.27 ± 0.03
2.48 ± 4.88
1.32± 0.25
3.2 ± 1.2
0.08 ± 0.05
1.45 ± 0.23
After > 6 weeks
treatement
211 ±38
2.7 ± 2.1
6.5 ± 3.2
18.6 ± 8.0
47 ± 17
2.4 ± 0.2
0.30 ± 0.07
0.29 ± 0.03
0.92 ± 1.35
1.27 ± 0.28
3.4 ± 1.3
0.11 ± 0.06a
1.53 ± 0.23
Reference interval
40 -200
1.0 - 5.0
1.8 - 6.6
< 27
50 -112
1.7 - 2.7
0.22 - 0.43
0.22 - 0.42
< 12
0.95 - 2.05
0.8 - 4.6
< 0.08
0.9 - 2.5
0.025 > p > 0.01
Tab. 2 Serum components before and after > 6 weeks of Roac-
cutane™ (40—60 mg/day) to young adults, (18 males and 2 fe-
males). Values are mean ± SD. (N = 5 except for apolipoprotein
B, where N = 9 and lipoprotein lipase and hepatic lipase, N = 16).
The reference intervals refer to men and women 20—60 years old.
Component
Sex hormone-binding globulin
Follitropin
Lutropin
Cholesterol
Triacylglycerol
HDL cholesterol
LDL cholesterol
Apolipoprotein· Β ,
Lipoprotein(a)
Lipoprotein lipase activity
Hepatic lipase activity
Collagen I telopeptide
Unit
fag/i)συ/1)συ/ΐ)
(mmol/l)
(mmol/1)
(mmol/l)
(mmol/1)
(g/1)(units/1)
(U/l)
(U/l)
(«Λ)
Before treatment
2.15 ± 1.1
3.7 ± 2.6
3.0 ± 2.2
4.19± 0.99
0.91 ± 0.13
1.17± 0.31
2.71 ± 0.95
0.74 ± 0.23
504 ± 473
68.6 ± 34.8
341.9 ± 126.5
11.9 ± 6.2
After > 6 weeks
treatment
1.8 ± 0.8
3.4 ± 2.0
2.1 ± 0.5
4.80 ± 1.34a
1.17 ± 0.61
1.14 ± 0.38
3.26 ± l.la
0.89 ± 0.2 lb
494 ± 390
59.6 ± 22.3
349.3 ± 153.6
11.0 ± 5.7
Reference interval
0.6 - 7.0
1 - 10
1 - 12
3.5 - 8.0
0.4- 1.8
0.7- 1.9
2.0 - 4.2
0.4- 1.3
<700
70 - 140
320 - 620
1.8- 5.0
a
 0.025 > ρ > 0.01 ρ < 0.01
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The effect of all-trans retinoic acid on the concentra-
tion of apolipoprotein B, therefore does not seem to
be direct (25). Increased levels of apolipoprotein B
may result from decreased clearance of apolipoprotein
B-containing lipoproteins, e. g. through decreased
LDL-receptor activity or from an increase in the pro-
duction rate of the triacylglycerol-rich apolipoprotein
B-containing lipoproteins. Apparently, decreased lipo-
protein lipase or hepatic lipase activities are not in-
volved (tab. 2).
The reasons for the discrepancy between the present in
vivo data and the in vitro observations (1—5), i.e. the
lack of change in serum concentrations of some of the
components listed in table 1, is not known. Obviously,
plasma concentrations result from the net contributions
of synthesis, distribution and elimination, each of which
may be the principal determinant of the actual plasma
concentration; thus, the impact of synthesis is not neces-
sarily decisive for plasma levels. However, it is also pos-
sible that the elevation of the concentration of all-trans
retinoic acid, the active retinoid, in serum to only 2-4
times the normal level, was too small, and that the con-
centrations of all-trans retinoic acid in the relevant tis-
sues (e. g. the liver) was insufficient to increase retinoic
acid receptor occupancy, so that transcription of the
genes in question was unaffected. Possibly, the all-trans
retinoic acid is sequestered in the tissues by protein
binding (e. g. to cellular retinoic acid binding proteins,
CRABPs, which are actually induced by all-trans reti-
noic acid (28)) and is therefore unavailable to the recep-
tors. Finally, it cannot be excluded that 14-hydroxy-retro
retinol (30) rather than all-trans retinoic acid is respons-
ible for many of the effects of vitamin A reported
(1).
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